Relmada in-licenses Tourette syndrome drug from Asarina

7 February 2025

US CNS specialist Relmada Therapeutics (Nasdaq: RLMD) has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma (STO: ASAP), being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.

Relmada noted that it has acquired full global ownership rights to sepranolone from Asarina through an asset purchase agreement for 3 million euros ($3.1 million).

Following the transfer of assets to Relmada, the Asarina board of directors intends to convene an extraordinary general meeting and propose to the shareholders that Asarina Pharma be liquidated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK